News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|March 21, 2025

CGM vs Traditional Monitoring

Author(s)Davida Kruger, MSN, APN-BC, BC-ADM , Jaime Murillo, MD, FACC, FASE , Ian Neeland, MD, FAHA, FACC

Experts discuss the clinical and practical factors that guide decision-making when recommending continuous glucose monitoring (CGM) vs traditional glucose monitoring for patients with type 2 diabetes.

Episodes in this series

1 KOL is featured in this series.

EP. 1 CGM: Redefining Type 2 Diabetes Management

EP. 2 Key Benefits of CGM Technology

EP. 2 Key Benefits of CGM Technology

EP. 3 CGM's Impact on Clinical Inertia

EP. 3 CGM's Impact on Clinical Inertia

EP. 4 CGM vs Traditional Monitoring

EP. 4 CGM vs Traditional Monitoring

EP. 5 Understanding CGM Metrics

EP. 5 Understanding CGM Metrics

EP. 6 Health Care System Integration

EP. 6 Health Care System Integration

EP. 7 CGM Coverage and Access

EP. 7 CGM Coverage and Access

EP. 8 Implementation Barriers

EP. 8 Implementation Barriers

EP. 9 Overcoming Access Challenges

EP. 9 Overcoming Access Challenges

EP. 10 Adoption Strategies

EP. 10 Adoption Strategies

EP. 11 The Metro Nashville Public Schools Initiative

EP. 11 The Metro Nashville Public Schools Initiative

EP. 12 Health Care Quality Impact

EP. 12 Health Care Quality Impact

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 13 Population Outcomes and Return on Value With CGMs

EP. 14 Long-Term Outcomes Assessment

EP. 14 Long-Term Outcomes Assessment

EP. 15 Closing Perspectives

EP. 15 Closing Perspectives

Video content above is prompted by the following:

What clinical and practical factors guide your decision-making when recommending CGMs versus vs traditional glucose monitoring for patients with type 2 diabetes?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 11th 2026

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

ByKen Cohen, MD,Samuel Wilkinson, MD,Greg Rhee, PhD, FACE,Michael E. Thase, MD,Nisha Bhide, PharmD

September 11th 2026

2 experts are featured in this video

Inside the Be-Well Trials: Design, Population, and Patient Selection

ByRaymond Chung, MD,Douglas Dieterich, MD

September 10th 2026

Counseling Vitiligo Patients on Time to Repigmentation

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

September 10th 2026

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare

ByRyan Haumschild, PharmD, MBA,David Rosmarin, MD,Seemal R. Desai, MD, FAAD,Jason Fehr, MA,Karan Lal, DO, MS, FAAD

September 10th 2026

Trending on AJMC

Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD

Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD

Amid SOHO Data, Reviewers of BTK Inhibitors in MCL Call for Trials

Counseling Vitiligo Patients on Time to Repigmentation

Cross-Trial Vitiligo Data: What Payers Can and Can't Compare